Estimates of illicit drug use during pregnancy by maternal interview, hair analysis, and meconium analysis
- PMID: 11241040
- DOI: 10.1067/mpd.2001.111429
Estimates of illicit drug use during pregnancy by maternal interview, hair analysis, and meconium analysis
Abstract
Objective: To compare the sensitivity and specificity of maternal interview, maternal hair analysis, and meconium analysis in detecting perinatal exposure to cocaine, opiate, and cannabinoid.
Design/methods: The use of cocaine, opiate, and cannabinoid during pregnancy was determined prospectively in 58 women by 3 methods: structured maternal interview, maternal hair analysis, and meconium analyses. The results of the 3 methods were compared with one another.
Results: The maternal interview showed the lowest sensitivity in detecting cocaine and opiate exposures (65% and 67%, respectively), but it had the highest sensitivity in detecting cannabinoid exposure (58%). Both hair and meconium analyses had high sensitivity for detecting cocaine or opiate exposures. Hair analysis had a sensitivity of 100% for cocaine and 80% for opiate detection. However, it had a false-positive rate of 13% for cocaine and 20% for opiate, probably as a result of passive exposure. Meconium analysis had a sensitivity of 87% for cocaine and 77% for opiate detection, but unlike hair analysis, it had no false-positive test results for cocaine. Both hair and meconium analyses had low sensitivity in detecting cannabinoid exposure (21%-22.7%), most probably because of the sporadic use of cannabinoid.
Conclusion: Meconium and hair analyses had the highest sensitivities for detecting perinatal use of cocaine and opiate, but not for cannabinoid. The principal drawback of hair analysis is its potential for false-positive test results associated with passive exposure to drugs. Maternal interview is a time-consuming test of low sensitivity. The high sensitivity of meconium analysis and the ease of collection make this test ideal for perinatal drug screening.
Similar articles
-
Drug screening in newborns and mothers using meconium samples, paired urine samples, and interviews.J Perinatol. 1995 May-Jun;15(3):199-202. J Perinatol. 1995. PMID: 7666268
-
Assessment of exposure to opiates and cocaine during pregnancy in a Mediterranean city: preliminary results of the "Meconium Project".Forensic Sci Int. 2005 Oct 4;153(1):59-65. doi: 10.1016/j.forsciint.2005.04.013. Forensic Sci Int. 2005. PMID: 15923097
-
Drug screening of newborns by meconium analysis: a large-scale, prospective, epidemiologic study.Pediatrics. 1992 Jan;89(1):107-13. Pediatrics. 1992. PMID: 1727992
-
Novel methods for the detection of drug and alcohol exposure during pregnancy: implications for maternal and child health.Clin Pharmacol Ther. 2008 Apr;83(4):631-4. doi: 10.1038/sj.clpt.6100506. Epub 2008 Feb 20. Clin Pharmacol Ther. 2008. PMID: 18288086 Review.
-
Drugs of abuse testing in meconium.Clin Chim Acta. 2006 Apr;366(1-2):101-11. doi: 10.1016/j.cca.2005.10.028. Epub 2006 Jan 17. Clin Chim Acta. 2006. PMID: 16413011 Review.
Cited by
-
A Systematic Review of Clinical Practice Guidelines for Neonatal Abstinence Syndrome.Children (Basel). 2023 Oct 13;10(10):1685. doi: 10.3390/children10101685. Children (Basel). 2023. PMID: 37892348 Free PMC article. Review.
-
Expression of the endocannabinoid system and response to cannabinoid components by the human fetal testis.BMC Med. 2023 Jul 11;21(1):219. doi: 10.1186/s12916-023-02916-5. BMC Med. 2023. PMID: 37430350 Free PMC article.
-
Impaired vision in children prenatally exposed to methadone: an observational cohort study.Eye (Lond). 2024 Jan;38(1):118-126. doi: 10.1038/s41433-023-02644-3. Epub 2023 Jul 4. Eye (Lond). 2024. PMID: 37402864 Free PMC article.
-
Drug exposure during pregnancy: Current understanding and approaches to measure maternal-fetal drug exposure.Front Pharmacol. 2023 Mar 23;14:1111601. doi: 10.3389/fphar.2023.1111601. eCollection 2023. Front Pharmacol. 2023. PMID: 37033628 Free PMC article. Review.
-
Pharmacokinetics of Cannabis and Its Derivatives in Animals and Humans During Pregnancy and Breastfeeding.Front Pharmacol. 2022 Jul 12;13:919630. doi: 10.3389/fphar.2022.919630. eCollection 2022. Front Pharmacol. 2022. PMID: 35903331 Free PMC article. Review.
